PMI’s FDA-approved SynCardia STAH is promising, but adoption and revenues lag; cash burn and dilution weigh. Read the full ...
Palantir Technologies Inc. faces steep downside risk as extreme valuation meets weakening signals and insider selling. Click ...
In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a marked attenuation of kidney function loss, suggesting a potential disease-modifying ...
Discover how to calculate shareholders' equity to assess a company's financial health. Learn the formula, components, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback